Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines
about
Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsRecent applications of chemosensitivity tests for colorectal cancer treatmentMechanism Profiling of Hepatotoxicity Caused by Oxidative Stress Using Antioxidant Response Element Reporter Gene Assay Models and Big DataPromoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.New challenges and inspired answers for anticancer drug discovery and developmentRaltitrexed: optimism and reality.The polar hydrophobicity of fluorinated compounds.Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse.Systems medicine: helping us understand the complexity of disease.Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees.Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors.Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.5-Fluorouracil accumulation in green microalgae and its biogenetic transfer into ciliate protozoan.Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.Genotype frequencies of drug-metabolizing enzymes responsible for purine and pyrimidine antagonists in a healthy Asian-Indian population.Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome.Enhanced antineoplastic/therapeutic efficacy using 5-fluorouracil-loaded calcium phosphate nanoparticles
P2860
Q26738655-1E5B9641-0091-4546-8EE8-AE40638B0980Q26851075-03DF8A87-72D3-488A-A7D0-4C9A435DC0E9Q28393835-3397A0E5-CFDB-43D7-8555-AE3EDDE7284FQ30988828-0385C585-C464-48A4-B22D-1115D387FE0FQ33628778-77CCC57F-8A74-4218-991E-B194153D7547Q34981175-ED96099D-7482-4B1E-999B-CA32BAE61AD1Q35009893-36255A52-1BEC-4566-B067-DFDB1CF33C76Q35762540-49141A63-6E00-4A56-B0D3-FE392DA42C31Q36441493-8734D577-4D68-4F60-B419-13B68C33D0D6Q36908719-FEB401A5-C59D-4D93-97E6-A695A177EC7AQ38125669-B46CC04A-4AA9-4230-9F2E-3DF707898F16Q38432054-6E460E38-2978-404C-BBD0-EF018E4F1725Q38943220-3E55C835-789F-42EC-95ED-2475349262B7Q38961918-B1C7ED74-3887-46C4-AAD1-BCD02BF58AF3Q42961795-2A52B998-EDB5-4409-A225-4E8E7FDC65C7Q44991007-488D6C5A-40A4-4D04-800C-373FF6C3BE4FQ46866916-D1607720-1DFD-4378-BB05-1D43D26B9613Q50502179-3AA3EF90-36E5-45AC-9E91-28D58AA919D5Q54263942-38DEBDBE-58B5-4546-B336-9244143F342AQ54310189-466E990A-62DF-485A-A774-2E22FE79FB13Q54571689-543DC772-D965-4F03-BF15-A67967EDE778Q57821940-5F529B77-804E-42A2-BE79-B9E1CB0D36CC
P2860
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@ast
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@en
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@nl
type
label
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@ast
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@en
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@nl
prefLabel
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@ast
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@en
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@nl
P3181
P1476
Clinical implications of dihyd ...... D inhibitory fluoropyrimidines
@en
P2093
Kenji Omura
P2888
P3181
P356
10.1007/S10147-003-0330-Z
P407
P577
2003-06-01T00:00:00Z